Biotechnology

Abridge unveils a sweeping AI platform to combat clinician burnout and mend a fragmented system by linking care delivery, payment, and research.

In memory of her daughter Elora, a mother's foundation joins a global research network, turning personal tragedy into a collaborative fight against a rare cancer.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

Probiogen's 'Probiotic of the Year' award isn't just a win for the brand; it marks a pivotal moment for functional supplements and conscious consumerism.

Despite a dip in NAV, Northern Venture Trust raises £30M and maintains dividends, bracing for the impact of a major VCT tax relief cut on UK startups.

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.

With a promising cancer therapy but precarious finances, Propanc Biopharma's stock buyback raises a critical question: is it a sign of confidence or a high-stakes gamble?

A novel case study reveals how targeted chemotherapy delivery is outsmarting stubborn tumors, highlighting a metabolic victory even when size remains unchanged.

Herbs, Etc. just won Superfood of the Year. We explore how a legacy brand uses 57 years of integrity to innovate and thrive in today's crowded market.

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

RenX just wiped $7M of debt in a savvy insider deal. It’s more than a balance sheet fix—it’s a calculated bet on a tech-driven, sustainable future.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

Relmada Therapeutics poaches a Sage neurosteroid expert for its sepranolone program. A look at the strategic rationale behind a move that signals big ambitions.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

Shanghai is launching a massive tech festival in 2026. Is it a genuine gateway for global firms or a carefully curated showcase of China's industrial might?